



ASX ANNOUNCEMENT

Actinogen Medical appoints new Non-Executive Director

Sydney, 4 April 2019: Actinogen Medical ASX: ACW ('ACW' or 'the Company') is pleased to announce the appointment of Malcolm McComas as a Non-Executive Director of the Company.

Mr. McComas brings over 25 years of experience in the financial services industry with extensive experience in corporate finance, M&A, debt and equity funding transactions across multiple industry sectors. He previously held senior leadership roles with Grant Samuel, County NatWest (now Citigroup) and Morgan Grenfell (now Deutsche Bank) in Australia and the UK. Prior to this, Mr. McComas was a lawyer at Herbert Geer, specialising in tax.

Mr. McComas is an experienced company director and currently serves as Chairman of Pharmaxis (ASX: PXS) and Fitzroy River Corporation (ASX:FZR) and as a director of Saunders International (ASX: SND) and Royalco Resources (ASX: RCO). He was previously a director of BC Iron (ASX:BCI) and other entities.

Mr. McComas also has not-for-profit involvement as a director the Australasian Leukemia and Lymphoma Group and peak body experience as a former president of the Financial Services Institute of Australia (FINSIA). He is a Fellow of the Australian Institute of Company Directors and holds degrees in Law and Economics from Monash University in Melbourne.

Commenting on the new appointment, Actinogen Chairman, Dr Geoff Brooke said: "We are delighted to welcome Malcolm to the Actinogen Board. His experience in financial services, specifically in transactional and funding matters, will be of significant value as Actinogen enters the next phase of growth. The appointment of Malcom is highly complementary to the Board's existing mix of skills and experience and we look forward to his contribution."

As a condition of his appointment, Mr McComas will be granted 3.0 million options, subject to shareholder approval, if required. The exercise price of the options will be \$0.10 per option. The options will expire 5 years from the date of commencement of the directorship and the options will vest quarterly over a period of 3 years from the date of grant (in each case, subject to continuous service as a Director during the period from the date of grant up to and including applicable vesting date).

ENDS

Actinogen Medical

Dr. Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401
E: bill.ketelbey@actinogen.com.au

 @BillKetelbey

Investor and Media Enquiries

Arthur Chan
WE Buchan
M: +61 2 9237 2805
E: arthurc@we-buchan.com

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing its lead compound Xanamem, as a promising new therapy for Alzheimer's disease, a condition with a multibillion-dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn and is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia.

About Xanamem™

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

About XanADu

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu has fully enrolled 186 patients from 25 research sites across Australia, the UK and the USA. Results are expected in Q2 2019. The trial is registered on www.clinicaltrials.gov with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

About XanaHES

XanaHES is a Phase I, randomised, single blinded, central reader blinded, placebo-controlled, dose escalation study to assess the safety and tolerability of Xanamem™ 20mg & 30mg once daily in healthy elderly volunteers. Changes in cognitive performance from baseline to end-of-treatment will be measured as an exploratory efficacy outcome.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.